New anticoagulants in combination with antiplatelet agents
Tidsskr Nor Laegeforen. 2016 Oct 11;136(18):1543-1546.
doi: 10.4045/tidsskr.15.1356.
eCollection 2016 Oct.
[Article in
English,
Norwegian]
Affiliations
- 1 Nevrologisk avdeling Klinikk for kirurgi og nevrofag Oslo universitetssykehus, Rikshospitalet.
- 2 Medisinsk avdeling Sykehuset Østfold.
- 3 Nevrologisk avdeling Klinikk for kirurgi og nevrofag Oslo universitetssykehus, Rikshospitalet og Institutt for klinisk medisin Universitetet i Oslo.
- 4 Kardiologisk avdeling B Oslo universitetssykehus, Ullevål og Institutt for klinisk medisin Universitetet i Oslo.
- 5 Medisinsk avdeling Sykehuset Østfold og Institutt for klinisk medisin Universitetet i Oslo.
Abstract
The use of new, direct anticoagulants is increasing. Data from both controlled trials and clinical practice have shown that these drugs are as efficacious and safe as warfarin for deep vein thrombosis and pulmonary embolism, and as stroke prophylaxis for patients with atrial fibrillation. But what if platelet inhibition is also indicated? In the following, the combination of antiplatelets and the new anticoagulants is discussed for various indications.
MeSH terms
-
Acute Coronary Syndrome / drug therapy
-
Anticoagulants* / administration & dosage
-
Anticoagulants* / therapeutic use
-
Atrial Fibrillation / drug therapy
-
Coronary Disease / drug therapy
-
Drug Therapy, Combination
-
Humans
-
Platelet Aggregation Inhibitors* / administration & dosage
-
Platelet Aggregation Inhibitors* / therapeutic use
-
Stroke / prevention & control
-
Venous Thromboembolism / drug therapy
-
Venous Thrombosis / drug therapy
Substances
-
Anticoagulants
-
Platelet Aggregation Inhibitors